Using magnesium sulfate with bupivacaine for pain relief after hip surgery
Efficacy of Adding Magnesium Sulfate to Bupivacaine in Ultrasound-guided Transmuscular Quadratus Lumborum Block for Postoperative Analgesia in Patients Underdoing Hip Arthroplasty
PHASE2; PHASE3 · Tanta University · NCT06956950
This study is testing if adding magnesium sulfate to a pain relief shot can help adults feel less pain and use fewer opioids after hip surgery.
Quick facts
| Phase | PHASE2; PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tanta University (other) |
| Locations | 1 site (Tanta, El-Gharbia) |
| Trial ID | NCT06956950 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of adding magnesium sulfate to bupivacaine in an ultrasound-guided transmuscular quadratus lumborum block for postoperative pain management in adults undergoing hip arthroplasty. The study aims to determine if magnesium sulfate can reduce pain scores and total opioid consumption compared to a placebo. Participants will receive either the combination of magnesium sulfate and bupivacaine or bupivacaine with saline, followed by monitoring for pain and side effects for 48 hours post-surgery.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older, classified as ASA class I-III, who are scheduled for hip arthroplasty.
Not a fit: Patients with a BMI over 40, allergies to local anesthetics or magnesium sulfate, or severe renal impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved pain management and reduced opioid use after hip arthroplasty.
How similar studies have performed: Previous studies have shown promising results with the addition of magnesium sulfate in regional anesthesia techniques, suggesting potential efficacy in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * American Society of Anesthesiology (ASA) class I-III * Undergoing hip arthroplasty . Exclusion Criteria: * Patient refusal. * Body mass index (BMI) \> 40 Kg/m2. * Allergy to local anesthetics or magnesium sulphate. * coexisting coagulopathy. * Local infection at puncture site. * Severe renal impairment ( eGFR \< 30 ml/min)
Where this trial is running
Tanta, El-Gharbia
- Faculty of medicine — Tanta, El-Gharbia, Egypt (RECRUITING)
Study contacts
- Principal investigator: Mostafa Mohammad Abdelsattar Elbagoury, MD — lecturer of anesthesia and surgical ICU and pain medicine
- Study coordinator: Mostafa Mohammad Abdelsattar Elbagoury, MD
- Email: mostafa.elbagoury@med.tanta.edu.eg
- Phone: +201116297741
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pain Score Reduction